Boston Scientific ((BSX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Boston Scientific is currently conducting a study titled ‘A Prospective, Multi-center Study to Evaluate Efficacy and Safety of BSJ020R in Treatment of AVF for Hemodialysis’ (RANGER AV Japan Study). The primary aim is to assess the efficacy and safety of the RANGER™ Paclitaxel Coated Balloon in treating arteriovenous fistula (AVF) stenosis, a condition crucial for patients undergoing hemodialysis. This study is significant as it could potentially improve vascular access for dialysis patients, enhancing their quality of life.
The intervention being tested is the RANGER™ Paclitaxel Coated Balloon Catheter, a device designed to open blocked blood vessels using a balloon coated with the drug paclitaxel. This procedure aims to restore normal blood flow in patients with AVF stenosis.
The study follows an interventional design with a single-group model, focusing on treatment as its primary purpose. There is no masking involved in the study, meaning all participants and researchers are aware of the intervention being administered.
The study began on October 9, 2024, with the latest update submitted on September 16, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
For investors, the ongoing study by Boston Scientific could influence stock performance positively if the results demonstrate significant efficacy and safety improvements. The successful development of this device could also position Boston Scientific favorably against competitors in the vascular access market.
The study is currently recruiting, and further details can be accessed on the ClinicalTrials portal.